focus -WSS

focus

author：explore 2025-09-30 16:26:15 - browse：3215

Outgoing Bristol CEO Giovanni Caforio Emilie Pickering for STAT

It’s changing of the guard time at pharmaceutical giant Bristol Myers Squibb. On Wednesday, CEO Giovanni Caforio will step down. He’ll be replaced by Christopher Boerner, who is currently chief operating officer.

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market. But Bristol stumbled in 2016 when its immunotherapy Opdivo failed to help patients with non-small cell cancer more than chemotherapy. Opdivo remained a big seller, but its failure allowed Merck’s rival Keytruda to move into position to become the best-selling medicine in the world. In 2019, Caforio tried to flip the script, buying the biotech Celgene for $74 billion.

STAT recently sat down with Caforio, 59, to look back on what went wrong and right with his tenure. He also reflected on what it meant to be a physician — and the son of a physician. “We were speaking about patient stories over lunch and dinner, when I was a kid, and I think that drove my passion for medicine,” he said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Supreme Court to hear if Covid misinformation is protected speech

WSS

The White House hikes tariffs on plastic syringes made in China

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

A new drug could help frostbite victims avoid its ravages

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

Hospitals are piloting generative AI tools as regulators play catch

Congress may force more Covid

leisure time

focus

focus

Sports medicine is finally prioritizing gender equality

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Affirmative action in medical school literally saved lives

In 'major milestone,' FDA approves first cell therapy for solid tumors

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hospitals are piloting generative AI tools as regulators play catch

Medicare proposal to cover medical devices draws a mixed reaction

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Medicare proposal to cover medical devices draws a mixed reaction

Boston hospital trains restaurant workers on naloxone for overdoses

leisure time

CVS is willing to dump 10% of its Medicare Advantage members

Flagship Pioneering startup Sonata Therapeutics lays off 21

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Supreme Court to hear if Covid misinformation is protected speech

Obesity drug from Roche shows promise in early study

A new drug could help frostbite victims avoid its ravages

knowledge

entertainment

focus

hotspot